Genetic S.p.A Polfarmex S.A.

Poland

All drugs from this manufacturer

  • ASARIS PMDI

    The medicine is used to prevent breathing disorders occurring in asthma. It helps to prevent shortness of breath and wheezing.

    Dosage form: aerosol, inhalation suspension

    Active substance Dosage
    fluticasone propionate 50 mcg
    salmeterol xinafoate 36.32 mcg

    ATC: R03AK06

  • The medicine is used for the treatment of bronchial asthma (in individuals requiring long-term anti-inflammatory treatment), croup syndrome (acute inflammation of the larynx, trachea, and bronchi characterized, among other things, by a barking cough), and exacerbations of chronic obstructive pulmonary disease (COPD).

    Dosage form: suspension for nebulization

    Active substance Dosage
    budesonide 0.25 mg/ml

    ATC: R03BA02

  • The medicine is used in the treatment of bronchial asthma (in individuals requiring long-term use of glucocorticosteroids), in cases of croup syndrome (acute inflammation of the larynx, trachea, and bronchi manifesting as shortness of breath or a barking cough), and in exacerbations of chronic obstructive pulmonary disease (COPD).

    Dosage form: suspension for nebulization

    Active substance Dosage
    budesonide 0.5 mg/ml

    ATC: R03BA02